LGALS7B

Summary

LGALS7B (galectin 7B, HGNC:34447) is a protein-coding gene on chromosome 19q13.2, encoding Galectin-7 (P47929). Could be involved in cell-cell and/or cell-matrix interactions necessary for normal growth control.

The galectins are a family of beta-galactoside-binding proteins implicated in modulating cell-cell and cell-matrix interactions. Differential and in situ hybridization studies indicate that this lectin is specifically expressed in keratinocytes and found mainly in stratified squamous epithelium. A duplicate copy of this gene (GeneID:3963) is found adjacent to, but on the opposite strand on chromosome 19.

Source: NCBI Gene 653499 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 21 total
• Druggable target: yes
• MANE Select transcript: NM_001042507

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:34447
Approved symbol	LGALS7B
Name	galectin 7B
Location	19q13.2
Locus type	gene with protein product
Status	Approved
Aliases	GAL7
Ensembl gene	ENSG00000178934
Ensembl biotype	protein_coding
OMIM	617139
Entrez	653499

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 1 protein_coding, 1 retained_intron

ENST00000314980, ENST00000600304

RefSeq mRNA: 1 — MANE Select: NM_001042507 NM_001042507

CCDS: CCDS42565

Canonical transcript exons

ENST00000314980 — 4 exons

Exon	Start	End
ENSE00002443934	38789200	38789232
ENSE00002444531	38790689	38790890
ENSE00002498739	38789616	38789704
ENSE00003178102	38791580	38791754

Expression profiles

Bgee: expression breadth ubiquitous, 111 present calls, max score 99.76.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.8099 / max 274.5322, expressed in 61 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
175663	0.8099	61

Top tissues by expression

133 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
skin of abdomen	UBERON:0001416	99.76	gold quality
zone of skin	UBERON:0000014	99.61	gold quality
lower esophagus mucosa	UBERON:0035834	99.58	gold quality
skin of leg	UBERON:0001511	99.50	gold quality
esophagus mucosa	UBERON:0002469	98.92	gold quality
vagina	UBERON:0000996	93.41	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	85.72	gold quality
esophagus	UBERON:0001043	83.58	gold quality
minor salivary gland	UBERON:0001830	81.11	gold quality
saliva-secreting gland	UBERON:0001044	80.05	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	77.60	gold quality
spleen	UBERON:0002106	75.75	gold quality
gastrocnemius	UBERON:0001388	73.12	gold quality
ectocervix	UBERON:0012249	71.07	gold quality
right lung	UBERON:0002167	69.58	gold quality
mucosa of stomach	UBERON:0001199	69.41	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	69.23	gold quality
heart left ventricle	UBERON:0002084	68.81	gold quality
thoracic mammary gland	UBERON:0005200	68.53	gold quality
apex of heart	UBERON:0002098	68.51	gold quality
right atrium auricular region	UBERON:0006631	68.31	gold quality
body of stomach	UBERON:0001161	68.27	gold quality
right lobe of liver	UBERON:0001114	67.96	gold quality
omental fat pad	UBERON:0010414	67.87	gold quality
subcutaneous adipose tissue	UBERON:0002190	67.83	gold quality
uterine cervix	UBERON:0000002	67.81	gold quality
popliteal artery	UBERON:0002250	67.65	gold quality
tibial artery	UBERON:0007610	67.62	gold quality
adipose tissue	UBERON:0001013	67.31	gold quality
right lobe of thyroid gland	UBERON:0001119	67.09	gold quality

Single-cell (SCXA)

Detected in 7 experiment(s), a significant marker in 6.

Experiment	Marker?	Max mean expression
E-MTAB-8142	yes	1854.80
E-HCAD-1	yes	285.56
E-MTAB-8221	yes	240.03
E-MTAB-6653	yes	193.68
E-GEOD-139324	yes	42.16
E-ANND-3	yes	35.59
E-MTAB-10596	no	3243.62

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): TAF1

Literature-anchored findings (GeneRIF, showing 2)

• An association was seen between the level of presence of galectins-1 and -7 and neoplastic progression of hypopharyngeal and laryngeal squamous cell carcinomas. (PMID:18315601)
• serum concentration was significantly elevated in women (weeks 10-12 and 17-20) who subsequently developed pre-eclampsia (PMID:24534543)

Cross-species orthologs

24 orthologs

Organism	Symbol	Gene ID
danio_rerio	lgals3b	ENSDARG00000044001
danio_rerio	si:dkey-95h12.2	ENSDARG00000092923
mus_musculus	Lgals7	ENSMUSG00000053522
rattus_norvegicus	Lgals7	ENSRNOG00000020380
drosophila_melanogaster	galectin	FBGN0031213
drosophila_melanogaster	CG11374	FBGN0031214
drosophila_melanogaster	CG13950	FBGN0031289
caenorhabditis_elegans		WBGENE00002264
caenorhabditis_elegans		WBGENE00002266
caenorhabditis_elegans		WBGENE00002269
caenorhabditis_elegans		WBGENE00002270
caenorhabditis_elegans		WBGENE00002271
caenorhabditis_elegans		WBGENE00004165
caenorhabditis_elegans	C27C7.5	WBGENE00007768
caenorhabditis_elegans	F46A8.3	WBGENE00009746
caenorhabditis_elegans	F46A8.4	WBGENE00009747
caenorhabditis_elegans	F46A8.5	WBGENE00009748
caenorhabditis_elegans	F46A8.8	WBGENE00009751
caenorhabditis_elegans		WBGENE00017080
caenorhabditis_elegans		WBGENE00018255
caenorhabditis_elegans		WBGENE00018649
caenorhabditis_elegans		WBGENE00018650
caenorhabditis_elegans		WBGENE00018651
caenorhabditis_elegans		WBGENE00235368

Paralogs (16): LGALS14 (ENSG00000006659), LGALS2 (ENSG00000100079), LGALS1 (ENSG00000100097), LGALS13 (ENSG00000105198), CLC (ENSG00000105205), LGALS8 (ENSG00000116977), LGALSL (ENSG00000119862), LGALS3 (ENSG00000131981), LGALS12 (ENSG00000133317), LGALS9 (ENSG00000168961), LGALS9B (ENSG00000170298), LGALS4 (ENSG00000171747), LGALS9C (ENSG00000171916), LGALS7 (ENSG00000205076), LGALS16 (ENSG00000249861), GRIFIN (ENSG00000275572)

Protein

Protein identifiers

Galectin-7 — P47929 (reviewed: P47929)

Alternative names: HKL-14, PI7, p53-induced gene 1 protein

All UniProt accessions (1): P47929

UniProt curated annotations — full annotation on UniProt →

Function. Could be involved in cell-cell and/or cell-matrix interactions necessary for normal growth control. Pro-apoptotic protein that functions intracellularly upstream of JNK activation and cytochrome c release.

Subunit / interactions. Monomer.

Subcellular location. Cytoplasm. Nucleus. Secreted.

Tissue specificity. Mainly expressed in stratified squamous epithelium.

Induction. By p53/TP53.

RefSeq proteins (1): NP_001035972* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001079	Galectin_CRD	Domain
IPR013320	ConA-like_dom_sf	Homologous_superfamily
IPR044156	Galectin-like	Family

Pfam: PF00337

UniProt features (15 total): strand 10, chain 1, domain 1, helix 1, binding site 1, turn 1

Structure

Experimental structures (PDB)

35 structures, top 30 by resolution.

PDB	Method	Resolution (Å)
3ZXF	X-RAY DIFFRACTION	1.38
4UW3	X-RAY DIFFRACTION	1.48
3ZXE	X-RAY DIFFRACTION	1.67
6VTO	X-RAY DIFFRACTION	1.69
4UW4	X-RAY DIFFRACTION	1.77
4UW6	X-RAY DIFFRACTION	1.79
7TRO	X-RAY DIFFRACTION	1.8
7XAC	X-RAY DIFFRACTION	1.8
5H9S	X-RAY DIFFRACTION	1.82
7N57	X-RAY DIFFRACTION	1.83
7TKX	X-RAY DIFFRACTION	1.83
7TKZ	X-RAY DIFFRACTION	1.83
7TKW	X-RAY DIFFRACTION	1.85
1BKZ	X-RAY DIFFRACTION	1.9
3GAL	X-RAY DIFFRACTION	1.9
6VTS	X-RAY DIFFRACTION	1.9
5H9Q	X-RAY DIFFRACTION	1.93
4GAL	X-RAY DIFFRACTION	1.95
6VTQ	X-RAY DIFFRACTION	1.95
7N8G	X-RAY DIFFRACTION	1.95
7TRN	X-RAY DIFFRACTION	1.95
2GAL	X-RAY DIFFRACTION	2
5GAL	X-RAY DIFFRACTION	2
7XBL	X-RAY DIFFRACTION	2
4UW5	X-RAY DIFFRACTION	2.04
7N4O	X-RAY DIFFRACTION	2.05
7N6C	X-RAY DIFFRACTION	2.1
4XBQ	X-RAY DIFFRACTION	2.23
6VTP	X-RAY DIFFRACTION	2.3
6VTR	X-RAY DIFFRACTION	2.3

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P47929-F1	96.80	0.95

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (1): 70–76

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-9725554	Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin
R-HSA-1266738	Developmental Biology
R-HSA-9734767	Developmental Cell Lineages

MSigDB gene sets: 17 (showing top): GOBP_HETEROPHILIC_CELL_CELL_ADHESION, GOBP_CELL_CELL_ADHESION, BLANCO_MELO_BRONCHIAL_EPITHELIAL_CELLS_INFLUENZA_A_INFECTION_DN, TRAVAGLINI_LUNG_BASAL_CELL, TRAVAGLINI_LUNG_PROXIMAL_BASAL_CELL, TRAVAGLINI_LUNG_PROLIFERATING_BASAL_CELL, GOBP_CELL_ADHESION, HE_LIM_SUN_FETAL_LUNG_C1_LATE_BASAL_CELL, HE_LIM_SUN_FETAL_LUNG_C1_MID_BASAL_CELL, HE_LIM_SUN_FETAL_LUNG_C1_PROXIMAL_BASAL_CELL, HE_LIM_SUN_FETAL_LUNG_C3_LYMPHATIC_ENDOTHELIAL_CELL, HE_LIM_SUN_FETAL_LUNG_C3_SCG3_POS_LYMPHATIC_ENDOTHELIAL_CELL, REACTOME_DIFFERENTIATION_OF_KERATINOCYTES_IN_INTERFOLLICULAR_EPIDERMIS_IN_MAMMALIAN_SKIN, REACTOME_DEVELOPMENTAL_CELL_LINEAGES, REACTOME_DEVELOPMENTAL_CELL_LINEAGES_OF_THE_INTEGUMENTARY_SYSTEM

GO Biological Process (2): apoptotic process (GO:0006915), heterophilic cell-cell adhesion (GO:0007157)

GO Molecular Function (2): carbohydrate binding (GO:0030246), protein binding (GO:0005515)

GO Cellular Component (5): obsolete extracellular space (GO:0005615), nucleus (GO:0005634), cytoplasm (GO:0005737), extracellular exosome (GO:0070062), extracellular region (GO:0005576)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Developmental Cell Lineages of the Integumentary System	1
Developmental Biology	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	2
cellular anatomical structure	2
programmed cell death	1
apoptotic signaling pathway	1
execution phase of apoptosis	1
cell-cell adhesion	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
extracellular vesicle	1

Protein interactions and networks

STRING

768 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
LGALS7B	LGALS3BP	Q08380	905
LGALS7B	BCL2	P10415	820
LGALS7B	SMAD3	P84022	698
LGALS7B	PAICS	P22234	669
LGALS7B	CHD7	Q9P2D1	602
LGALS7B	SELE	P16111	511
LGALS7B	KRTDAP	P60985	509
LGALS7B	H4C16	P02304	493
LGALS7B	H4C7	Q99525	486
LGALS7B	MGAT5	Q09328	470
LGALS7B	CTR9	Q6PD62	461
LGALS7B	SBSN	Q6UWP8	452
LGALS7B	UCHL5	Q9Y5K5	443
LGALS7B	HCFC1	P51610	439
LGALS7B	CD209	Q9NNX6	436

IntAct

143 interactions, top by confidence:

A	B	Type	Score
JADE1	KAT7	psi-mi:“MI:0914”(association)	0.720
AEBP2	EED	psi-mi:“MI:0914”(association)	0.650
RCCD1	SPAG9	psi-mi:“MI:0914”(association)	0.640
CCNC	MED19	psi-mi:“MI:0914”(association)	0.640
LGALS7	DDIT4L	psi-mi:“MI:0915”(physical association)	0.560
LGALS7	TAB1	psi-mi:“MI:0915”(physical association)	0.560
LGALS7	SSBP1	psi-mi:“MI:0915”(physical association)	0.560
LGALS7	YAF2	psi-mi:“MI:0915”(physical association)	0.560
HSPA6	LGALS7	psi-mi:“MI:0915”(physical association)	0.560
LGALS7	LSM2	psi-mi:“MI:0915”(physical association)	0.560
TGM5	LGALS7	psi-mi:“MI:0915”(physical association)	0.560
TBC1D22B	A2ML1	psi-mi:“MI:0914”(association)	0.530
RBM24	PPL	psi-mi:“MI:0914”(association)	0.530
ZSCAN12	A2ML1	psi-mi:“MI:0914”(association)	0.530
GDF5	SERPINB7	psi-mi:“MI:0914”(association)	0.530
SSBP2	CLEC18A	psi-mi:“MI:0914”(association)	0.530
E6	CASK	psi-mi:“MI:0914”(association)	0.520
Tax	TAX1BP3	psi-mi:“MI:0914”(association)	0.520
ESR1		psi-mi:“MI:0914”(association)	0.460
LGALS7	S	psi-mi:“MI:0407”(direct interaction)	0.440
LGALS7	LGALS7	psi-mi:“MI:0407”(direct interaction)	0.440
	GNAT3	psi-mi:“MI:0915”(physical association)	0.400
Xpo1	IFT56	psi-mi:“MI:0914”(association)	0.350
DAG1	AGRN	psi-mi:“MI:0914”(association)	0.350

BioGRID (249): LGALS7 (Affinity Capture-MS), LGALS7 (Affinity Capture-MS), LGALS7B (Affinity Capture-MS), LGALS7 (Affinity Capture-MS), LGALS7 (Affinity Capture-MS), LGALS7 (Affinity Capture-MS), LGALS7 (Affinity Capture-MS), TUBA3C (Affinity Capture-MS), LGALS7B (Affinity Capture-MS), USP4 (Affinity Capture-MS), DPYSL5 (Affinity Capture-MS), DPYSL4 (Affinity Capture-MS), NAMPT (Affinity Capture-MS), DPYSL2 (Affinity Capture-MS), GAB1 (Affinity Capture-MS)

ESM2 similar proteins: A8MUM7, C0HJQ1, C0HJR3, O00182, O00214, O08573, O44126, O54891, O54974, O55060, P05162, P07583, P09382, P11116, P11762, P16045, P23668, P36573, P38552, P47929, P47967, P48538, P56217, P56470, P61801, P81184, P97590, P97840, Q05315, Q09581, Q1ECW6, Q29058, Q3B8N2, Q3MHZ8, Q3T0D6, Q49I35, Q504A5, Q5R7M1, Q62665, Q68FJ4

Diamond homologs: A8MUM7, O00182, O08573, O54891, P38486, P38552, P47929, P79238, P97400, P97840, Q05315, Q29058, Q3B8N2, Q3MHZ8, Q3T0D6, Q6DKI2, Q8K419, Q8TCE9, Q9UHV8, A4D1Z8, C0HJQ1, C0HJR3, O00214, O44126, O54974, P05162, P07583, P08520, P08699, P09382, P11116, P11762, P16045, P16110, P23668, P26788, P47845, P47953, P48538, P56217

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

21 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	19
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

556 predictions. Top by Δscore:

Variant	Effect	Δscore
19:38790684:TCCA:T	acceptor_loss	1.0000
19:38790685:CCA:C	acceptor_loss	1.0000
19:38790686:CA:C	acceptor_loss	1.0000
19:38790687:A:AG	acceptor_gain	1.0000
19:38790687:AG:A	acceptor_gain	1.0000
19:38790688:G:GA	acceptor_gain	1.0000
19:38790688:GG:G	acceptor_gain	1.0000
19:38790688:GGT:G	acceptor_gain	1.0000
19:38790688:GGTT:G	acceptor_gain	1.0000
19:38790688:GGTTC:G	acceptor_gain	1.0000
19:38790887:CAAGG:C	donor_loss	1.0000
19:38790891:G:GC	donor_loss	1.0000
19:38790891:G:GG	donor_gain	1.0000
19:38790892:T:G	donor_loss	1.0000
19:38789229:GTCC:G	donor_gain	0.9800
19:38789233:G:GG	donor_gain	0.9800
19:38789701:GCAG:G	donor_gain	0.9800
19:38789702:CAG:C	donor_loss	0.9800
19:38789703:AG:A	donor_loss	0.9800
19:38789704:GGT:G	donor_loss	0.9800
19:38789705:GTGAG:G	donor_loss	0.9800
19:38791574:CTGCA:C	acceptor_loss	0.9800
19:38791575:TGCA:T	acceptor_loss	0.9800
19:38791576:GCAGG:G	acceptor_loss	0.9800
19:38791577:CAGGC:C	acceptor_loss	0.9800
19:38791578:A:T	acceptor_loss	0.9800
19:38791579:GGCC:G	acceptor_gain	0.9800
19:38789706:T:A	donor_loss	0.9700
19:38791578:A:AG	acceptor_gain	0.9700
19:38791579:G:GG	acceptor_gain	0.9700

AlphaMissense

877 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:38790803:G:C	W70C	0.991
19:38790803:G:T	W70C	0.991
19:38790886:T:C	F98S	0.990
19:38790801:T:A	W70R	0.989
19:38790801:T:C	W70R	0.989
19:38790690:T:C	F33L	0.988
19:38790691:T:C	F33S	0.988
19:38790692:C:A	F33L	0.988
19:38790692:C:G	F33L	0.988
19:38790745:T:C	F51S	0.988
19:38789674:T:A	I22N	0.987
19:38790852:T:C	F87L	0.987
19:38790854:C:A	F87L	0.987
19:38790854:C:G	F87L	0.987
19:38791610:T:C	F110L	0.987
19:38791611:T:C	F110S	0.987
19:38791612:C:A	F110L	0.987
19:38791612:C:G	F110L	0.987
19:38789674:T:C	I22T	0.984
19:38789686:T:A	V26D	0.984
19:38789679:G:C	G24R	0.982
19:38790782:C:A	N63K	0.982
19:38790782:C:G	N63K	0.982
19:38789674:T:G	I22S	0.981
19:38790749:C:A	N52K	0.981
19:38790749:C:G	N52K	0.981
19:38790865:T:G	I91S	0.981
19:38790703:T:C	L37P	0.979
19:38790865:T:A	I91N	0.979
19:38789680:G:A	G24D	0.978

dbSNP variants (sampled 300 via entrez): RS1000840194 (19:38792200 C>T), RS1000870390 (19:38774633 C>G,T), RS1001858294 (19:38774562 T>C), RS1002374261 (19:38774353 C>T), RS1002388033 (19:38791400 TA>T,TAA), RS1002605566 (19:38792118 G>T), RS1002756687 (19:38775400 T>C), RS1003389401 (19:38788520 T>C), RS1005216986 (19:38774035 A>T), RS1006007088 (19:38791163 G>A), RS1006369016 (19:38789324 G>A), RS1007195063 (19:38788774 T>C,G), RS1007414434 (19:38788979 G>A), RS1008193733 (19:38787677 G>T), RS1008417963 (19:38787909 A>G)

Disease associations

OMIM: gene MIM:617139 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST006999_4	Logical memory (immediate recall) in mild cognitive impairment	4.000000e-07

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004874	memory performance

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5008 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

Binding affinities (BindingDB)

12 measured of 16 human assays (16 total across all organisms); most potent 12 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
N-[(2R,3R,4R,5S,6R)-5-{[(2S,3R,4S,5R,6R)-4-[(butylcarbamothioyl)amino]-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4-hydroxy-6-(hydroxymethyl)-2-methoxyoxan-3-yl]acetamide	KD	23000 nM
N-[(2R,3R,4R,5S,6R)-5-{[(2S,3R,4S,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-{[(3-hydroxypropyl)carbamothioyl]amino}oxan-2-yl]oxy}-4-hydroxy-6-(hydroxymethyl)-2-methoxyoxan-3-yl]acetamide	KD	23000 nM
N-[(2R,3R,4R,5S,6R)-5-{[(2S,3R,4S,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(prop-2-en-1-ylcarbamothioyl)amino]oxan-2-yl]oxy}-4-hydroxy-6-(hydroxymethyl)-2-methoxyoxan-3-yl]acetamide	KD	34000 nM
N-[(2R,3R,4R,5S,6R)-5-{[(2S,3R,4S,5R,6R)-4-[(cyclohexylcarbamothioyl)amino]-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4-hydroxy-6-(hydroxymethyl)-2-methoxyoxan-3-yl]acetamide	KD	40000 nM
N-[(2R,3R,4R,5S,6R)-5-{[(2S,3R,4S,5R,6R)-4-(carbamothioylamino)-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4-hydroxy-6-(hydroxymethyl)-2-methoxyoxan-3-yl]acetamide	KD	43000 nM
N-[(2R,3R,4R,5S,6R)-5-{[(2S,3R,4S,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-{[(pyridin-3-ylmethyl)carbamothioyl]amino}oxan-2-yl]oxy}-4-hydroxy-6-(hydroxymethyl)-2-methoxyoxan-3-yl]acetamide	KD	43000 nM
N-[(2R,3R,4R,5S,6R)-5-{[(2S,3R,4S,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(phenylcarbamothioyl)amino]oxan-2-yl]oxy}-4-hydroxy-6-(hydroxymethyl)-2-methoxyoxan-3-yl]acetamide	KD	45000 nM
N-[(2R,3R,4R,5S,6R)-5-{[(2S,3R,4S,5R,6R)-4-[(diethylcarbamothioyl)amino]-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4-hydroxy-6-(hydroxymethyl)-2-methoxyoxan-3-yl]acetamide	KD	46000 nM
N-[(2R,3R,4R,5S,6R)-5-{[(2S,3R,4S,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(methylcarbamothioyl)amino]oxan-2-yl]oxy}-4-hydroxy-6-(hydroxymethyl)-2-methoxyoxan-3-yl]acetamide	KD	49000 nM
N-[(2R,3R,4R,5S,6R)-5-{[(2S,3R,4S,5R,6R)-3,5-dihydroxy-4-{[(2-hydroxyethyl)carbamothioyl]amino}-6-(hydroxymethyl)oxan-2-yl]oxy}-4-hydroxy-6-(hydroxymethyl)-2-methoxyoxan-3-yl]acetamide	KD	49000 nM
N-[(2R,3R,4R,5S,6R)-5-{[(2S,3R,4S,5R,6R)-4-({[(2S,3R,4S,5R,6R)-2-{[(2R,3S,4R,5R,6R)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-methoxyoxan-3-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]carbamothioyl}amino)-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4-hydroxy-6-(hydroxymethyl)-2-methoxyoxan-3-yl]acetamide	KD	58000 nM
N-[(2R,3R,4R,5S,6R)-4-hydroxy-6-(hydroxymethyl)-2-methoxy-5-{[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-3-yl]acetamide	KD	70000 nM

ChEMBL bioactivities

12 potent at pChembl≥5 of 32 total, top 12 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
5.77	Kd	1700	nM	CHEMBL444662
5.70	Kd	2000	nM	CHEMBL1253726
5.68	Kd	2100	nM	CHEMBL503116
5.55	Kd	2800	nM	CHEMBL1253217
5.47	Kd	3400	nM	CHEMBL1253187
5.37	Kd	4300	nM	CHEMBL457221
5.33	Kd	4700	nM	CHEMBL1253745
5.30	Kd	5000	nM	CHEMBL1253744
5.27	Kd	5400	nM	CHEMBL1253742
5.12	Kd	7600	nM	CHEMBL516152
5.10	Kd	8000	nM	CHEMBL1253923
5.08	Kd	8300	nM	CHEMBL1253743

PubChem BioAssay actives

24 with measured affinity, of 281 total; 12 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
N-[(2S,3R,4S,5R,6R)-2-[(2S,3R,4S,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-(naphthalene-2-carbonylamino)oxan-2-yl]sulfanyl-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]naphthalene-2-carboxamide	412884: Binding affinity to galectin 7 at 0 degC by fluorescence polarization assay	kd	1.7000	uM
1-[(2S,3R,4S,5R,6R)-2-[(2S,3R,4S,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-[4-(2-phenylethylcarbamoyl)triazol-1-yl]oxan-2-yl]sulfanyl-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]-N-(2-phenylethyl)triazole-4-carboxamide	513982: Binding affinity to human galectin 7 at 4 degC by competitive fluorescence polarization assay	kd	2.0000	uM
N-[(2S,3R,4S,5R,6R)-2-[(2S,3R,4S,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(3-methoxybenzoyl)amino]oxan-2-yl]sulfanyl-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]-3-methoxybenzamide	412884: Binding affinity to galectin 7 at 0 degC by fluorescence polarization assay	kd	2.1000	uM
N-[(2S,3R,4S,5R,6R)-2-[(2R,3R,4S,5R,6R)-4-[(3,5-dimethoxybenzoyl)amino]-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]sulfanyl-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]-3,5-dimethoxybenzamide	513982: Binding affinity to human galectin 7 at 4 degC by competitive fluorescence polarization assay	kd	2.8000	uM
1-[(2S,3R,4S,5R,6R)-2-[(2S,3R,4S,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-[4-(prop-2-enylcarbamoyl)triazol-1-yl]oxan-2-yl]sulfanyl-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]-N-prop-2-enyltriazole-4-carboxamide	513982: Binding affinity to human galectin 7 at 4 degC by competitive fluorescence polarization assay	kd	3.4000	uM
N-[(2S,3R,4S,5R,6R)-2-[(2S,3R,4S,5R,6R)-4-benzamido-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]sulfanyl-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]benzamide	412884: Binding affinity to galectin 7 at 0 degC by fluorescence polarization assay	kd	4.3000	uM
1-[(2S,3R,4S,5R,6R)-2-[(2S,3R,4S,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-[4-(2-methoxyethylcarbamoyl)triazol-1-yl]oxan-2-yl]sulfanyl-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]-N-(2-methoxyethyl)triazole-4-carboxamide	513982: Binding affinity to human galectin 7 at 4 degC by competitive fluorescence polarization assay	kd	4.7000	uM
1-[(2S,3R,4S,5R,6R)-2-[(2S,3R,4S,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-[4-(2-hydroxypropylcarbamoyl)triazol-1-yl]oxan-2-yl]sulfanyl-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]-N-(2-hydroxypropyl)triazole-4-carboxamide	513982: Binding affinity to human galectin 7 at 4 degC by competitive fluorescence polarization assay	kd	5.0000	uM
N-butyl-1-[(2S,3R,4S,5R,6R)-2-[(2S,3R,4S,5R,6R)-4-[4-(butylcarbamoyl)triazol-1-yl]-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]sulfanyl-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]triazole-4-carboxamide	513982: Binding affinity to human galectin 7 at 4 degC by competitive fluorescence polarization assay	kd	5.4000	uM
N-[(2S,3R,4S,5R,6R)-2-[(2R,3S,4R,5R,6R)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-methoxyoxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]naphthalene-1-carboxamide	412884: Binding affinity to galectin 7 at 0 degC by fluorescence polarization assay	kd	7.6000	uM
1-[(2S,3R,4S,5R,6R)-2-[(2S,3R,4S,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-[4-(methylcarbamoyl)triazol-1-yl]oxan-2-yl]sulfanyl-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]-N-methyltriazole-4-carboxamide	513982: Binding affinity to human galectin 7 at 4 degC by competitive fluorescence polarization assay	kd	8.0000	uM
N-benzyl-1-[(2S,3R,4S,5R,6R)-2-[(2S,3R,4S,5R,6R)-4-[4-(benzylcarbamoyl)triazol-1-yl]-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]sulfanyl-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]triazole-4-carboxamide	513982: Binding affinity to human galectin 7 at 4 degC by competitive fluorescence polarization assay	kd	8.3000	uM

CTD chemical–gene interactions

14 total (human), top 14 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases expression, increases methylation	3
chloropicrin	decreases expression	2
dicrotophos	decreases expression	1
sodium arsenate	decreases expression, increases abundance	1
sodium arsenite	increases expression	1
perfluorooctanoic acid	decreases expression	1
cylindrospermopsin	increases expression	1
entinostat	increases expression	1
Air Pollutants	increases abundance, increases expression	1
Arsenic	increases abundance, decreases expression	1
Benzo(a)pyrene	affects methylation	1
Estradiol	decreases expression, affects cotreatment	1
Smoke	increases abundance, increases expression	1
Aflatoxin B1	increases expression	1

ChEMBL screening assays

17 unique, capped per target: 17 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1013548	Binding	Binding affinity to galectin 7 at 0 degC by fluorescence polarization assay	Galectin-inhibitory thiodigalactoside ester derivatives have antimigratory effects in cultured lung and prostate cancer cells. — J Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.